Lorne Infection & Immunity Conference 2014 Australia

> 19-21 February Mantra Lorne

**VICTORIAN INFECTION** & IMMUNITY NETWORK

# **Register Now!**

#### **Invited Speakers:**

**Preliminary Program** Bonnie Bassler, Princeton University, USA Facundo Batista, London Research Institute, UK now available online Brett Finlay, University of British Columbia, CAN Michael Gale, University of Washington, USA Adolfo García-Sastre, Mount Sinai, USA Thirumala-Devi Kanneganti, St Jude Children's Research Hospital, USA David Reddy, Medicines for Malaria Venture, SUI David Russell, Cornell University, USA

Alan Cowman, Walter and Eliza Hall Institute, VIC Tony Cunningham, Westmead Millennium Institute, NSW Dale Godfrey, University of Melbourne, VIC Phil Hansbro, University of Newcastle, NSW Edward Holmes, University of Sydney, NSW Jonathan Iredell, University of Sydney, NSW Alex Loukas, James Cook University, QLD Suresh Mahalingam, Griffith University, QLD Tania Sorrell, University of Sydney, NSW

### **Themes Include:**

E-NEWS

**DECEMBER 2013** 

Pathogenesis of infection Innate Immunity Adaptive Immunity Systems Biology **Emerging Infectious Diseases Clinical/Translational Research** Inflammatory Diseases **Microbiota and Immunity** Vaccines

### www.lorneinfectionimmunity.org

To add or update your Member Page email: info@viin.org.au







Murdoch Childrens

Healthier Kids. Healthier Fotore

Research Institute



Oral Healthcrc



Faculty of Medicine, Dentistry and Health Sciences Infection and Immunity Domain Microbiology and Immunology







VICTORIAN INFECTION & IMMUNITY NETWORK
DECEMBER 2013

### VIIN Industry Alliance BioBreakfast

In November 2013, the VIIN Industry Alliance and BioMelbourne Network joined together to co-host a BioBreakfast on *Emerging Superbugs – why we should be concerned and why we need a new approach*.

The event featured Professor Lindsay Grayson, Director of Infectious Diseases at Austin Health; <u>Professor Elizabeth</u> <u>Hartland</u>, Head of the Department of Microbiology and Immunology at the University of Melbourne and VIIN Co-convenor (pictured top right with Dr Melanie Thompson, Deakin University); Ms Cathy Cropp, Project Manager for BioDiem Ltd, a Melbourne-based company developing a novel antimicrobial compound; and Ms Suzanne Schultz (below left) from the University of Adelaide, who researches business models for incentivising the pharmaceutical industry to invest in antibiotic development.







The breakfast was well attended by representatives from Victoria's biotech and pharmaceutical companies and associated industries, VIIN scientists, the State Government and peak bodies.

For further information on the VIIN Industry Alliance and its activities contact Project Officer, Dr Rebecca Smith: Rebecca.Smith@monash.edu

For more photos visit the VIIN's Facebook Page: http://www.facebook.com/VictorianInfectionandImmunityNetwork

#### To contribute to this newsletter please email: info@viin.org.au

## NHMRC and ARC Success

Well done to all infection and immunity researchers who were successful in the recent rounds of NHMRC and ARC funding.

Of particular note was that Victorian infection and immunity researchers received close to 10% of the total pool of funds allocated by the NHMRC for funding beginning in 2014. This was made up of \$33mil for Project Grants and \$13.8mil worth of fellowship funding.

Keep up the good work!

## **VIIN Young Investigator Symposium**

VICTORIAN INFECTION & IMMUNITY NETWORK

Once again the annual VIIN Young Investigator Symposium was a great success with 200 attendees turning out at Walter and Eliza Hall Institute for the event. Professor Linfa Wang (CSIRO Australian Animal Health Laboratory and Duke-NUS, Singapore – pictured below left) gave the keynote presentation entitled From Hendra to Hollywood: a 16-year batty journey.




The quality of student and postdoctoral poster and oral presentations was outstanding. Jaclyn Pearson (University of Melbourne) was awarded the VIIN Young Investigator Award for her presentation, Never say die: NIeB antagonises death receptor signaling during bacterial gut *infection.* Jaclyn will now be presenting her work during the plenary session of the Lorne Infection and Immunity Conference in February 2014.

E-NEWS

**DECEMBER 2013** 

Other Prize Winners: Congratulations to Nollaig Bourke, Kim Lieu. Steven Mileto, Hamish McWilliam and Alison Browning, Monash University; Victoria Ryg-Cornejo and Lisa Mielke, Walter and Eliza Hall Institute

Symposium Sponsors: Thank to Biota, you Micromon. Life Technologies and Sapphire Bioscience.



Thank you also to the organising committee, prize judges and Walter and Eliza Hall Institute for hosting the symposium.

For more photos visit the VIIN's Facebook Page: http://www.facebook.com/VictorianInfectionandImmunityNetwork

To add or update your Member Page email: info@viin.org.au





Murdoch Childrens

Healthier Kids. Healthier Fotore

Research Institute



Oral Healthcrc



Faculty of Medicine, Dentistry and Health Sciences Infection and Immunity Domain Microbiology and Immunology







# Infection and Immunity Funding Opportunities

E-NEWS

**DECEMBER 2013** 

#### **Open Letter of Inquiry Global Health Grants**

Gates (Bill and Melinda) Foundation

The sponsor's Global Health Division aims to harness advances in science and technology to save lives in developing countries.

**Deadline:** Some grants in the Global Health Division are made through letter of inquiry (LOI). These areas include: Enteric & Diarrheal Diseases, HIV, Malaria, Neglected Infectious Diseases, Pneumonia, Tuberculosis. http://www.gatesfoundation.org/How-We-Work/General-Information/Grant-Opportunities/Open-LOI-Global-Health-Grants

#### Role of the Microflora in the Etiology of Gastro-Intestinal Cancer

VICTORIAN INFECTION & IMMUNITY NETWORK

National Cancer Institute/NIH/DHHS

National Cancer Institute (NCI) and National Institute on Alcohol Abuse and Alcoholism (NIAAA) invite applications for multidisciplinary research projects that will advance our mechanistic understanding of microflora influences on Gastro-Intestinal (GI) carcinogenesis. This FOA seeks applications that leverage and integrate information from large, meta-omic data sets to guide studies that identify critical microbial activities that can be mechanistically linked to GI carcinogenesis. Applicants may draw from existing large data sets, and may also propose to generate appropriate new data, including but not limited to data from both gene and protein analysis, such as DNA sequence and copy number, post-translational modifications, secreted signals, and protein-protein interaction data between host factors and individual microbial species, or communities of microbes. Applicants are encouraged to take advantage of existing methodologies and technologies developed by the microbiome and integrative cancer biology communities as well as other relevant technology sources, and to apply existing or new sophisticated data analysis, integration, and modeling methodologies to inform and guide hypothesis driven mechanistic studies on the role of the GI microflora during carcinogenesis. The common goal of the projects should be to understand how the resident microbes interact with the host and the host environment to prevent or enhance carcinogenesis in the GI tract. This FOA will use the NIH Research Project (R01) award mechanism.

**Deadline:** March 4, 2014, by 5:00 PM local time of applicant organisation. http://grants.nih.gov/grants/guide/pa-files/PAR-12-140.html

#### **Research to Advance Vaccine Safety**

National Institute of Allergy and Infectious Diseases/NIH/DHHS

The National Institutes of Health (NIH) and Centers for Disease Control and Prevention (CDC) invites studies that address scientific areas potentially relevant to vaccine safety such as 1) physiological and immunological responses to vaccines and vaccine components, 2) how genetic variations affect immune/physiological responses that may impact vaccine safety, 3) identification of risk factors and biological markers that may be used to assess whether there is a relationship between certain diseases or disorders and licensed vaccines, 4) creation/evaluation of statistical methodologies for analyzing data on vaccine safety, including data available from existing data sources such as passive reporting systems, or 5) the application of genomic/molecular technologies to improve knowledge of vaccine safety. This program will use the NIH Research Project (R01) award mechanism.

**Deadline:** The deadlines for receipt of standard R01 applications under this announcement are: February 5, June 5, and October 5 annually. The deadlines for receipt of AIDS-related applications are: January 7, May 7, and September 7 annually. This program will expire on January 8, 2015. http://grants1.nih.gov/grants/guide/pa-files/PA-12-037.html